Eli Lilly & Co., still hopeful about an experimental Alzheimer’s drug despite two disappointing studies, said it will do another one, probably in the third quarter of 2013 and focusing on patients with mild Alzheimer’s. This year, two clinical trials showed solanezumab did not significantly improve either the cognition or daily functioning of people with mild and moderate forms of the disease. But when those with mild Alzheimer’s were separated out, the drug was shown to significantly slow their decline in cognition.